PL1797109T3 - Mieszaniny polipeptydów, kompozycje zawierające je i procesy ich wytwarzania oraz ich zastosowania - Google Patents
Mieszaniny polipeptydów, kompozycje zawierające je i procesy ich wytwarzania oraz ich zastosowaniaInfo
- Publication number
- PL1797109T3 PL1797109T3 PL05795337.4T PL05795337T PL1797109T3 PL 1797109 T3 PL1797109 T3 PL 1797109T3 PL 05795337 T PL05795337 T PL 05795337T PL 1797109 T3 PL1797109 T3 PL 1797109T3
- Authority
- PL
- Poland
- Prior art keywords
- polypeptides
- mixtures
- processes
- compositions containing
- preparing same
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 2
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60884404P | 2004-09-09 | 2004-09-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
PL1797109T3 true PL1797109T3 (pl) | 2016-11-30 |
Family
ID=36037053
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL05795337.4T PL1797109T3 (pl) | 2004-09-09 | 2005-09-09 | Mieszaniny polipeptydów, kompozycje zawierające je i procesy ich wytwarzania oraz ich zastosowania |
Country Status (11)
Country | Link |
---|---|
US (2) | US7560100B2 (pl) |
EP (1) | EP1797109B1 (pl) |
CY (1) | CY1117704T1 (pl) |
DK (1) | DK1797109T3 (pl) |
ES (1) | ES2572811T3 (pl) |
HR (1) | HRP20160455T1 (pl) |
HU (1) | HUE028833T2 (pl) |
IL (1) | IL181802A (pl) |
PL (1) | PL1797109T3 (pl) |
SI (1) | SI1797109T1 (pl) |
WO (1) | WO2006029411A2 (pl) |
Families Citing this family (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000005250A1 (en) | 1998-07-23 | 2000-02-03 | Yeda Research And Development Co., Ltd | Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides |
ES2527760T3 (es) * | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
US6800287B2 (en) * | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
WO2002076503A1 (en) * | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
US7429374B2 (en) * | 2001-12-04 | 2008-09-30 | Teva Pharmaceutical Industries, Ltd. | Process for the measurement of the potency of glatiramer acetate |
GB0210397D0 (en) | 2002-05-07 | 2002-06-12 | Ferring Bv | Pharmaceutical formulations |
US8008258B2 (en) * | 2003-01-21 | 2011-08-30 | Yeda Research And Development Co. Ltd. | Cop 1 for treatment of inflammatory bowel diseases |
NZ546379A (en) * | 2003-10-31 | 2010-04-30 | Teva Pharma | Nanoparticles for drug delivery |
JP2007535498A (ja) * | 2004-03-03 | 2007-12-06 | テバ ファーマシューティカル インダストリーズ リミティド | グラチラマー・アセテートおよびリルゾールでの併用療法 |
EP1761276B1 (en) * | 2004-06-25 | 2013-07-24 | ID Biomedical Corporation of Quebec | Compositions and methods for treating neurological disorders |
SI1797109T1 (sl) * | 2004-09-09 | 2016-07-29 | Yeda Research And Development Co., Ltd. | Zmesi polipeptidov, sestavki, ki jih vsebujejo, in postopki za njihovo pripravo ter njihove uporabe |
NZ554018A (en) * | 2004-09-09 | 2009-06-26 | Teva Pharma | Process for preparation of trifluoroacetyl glatiramer acetate using purified hydrobromic acid |
US8324641B2 (en) * | 2007-06-29 | 2012-12-04 | Ledengin, Inc. | Matrix material including an embedded dispersion of beads for a light-emitting device |
WO2006083608A1 (en) * | 2005-02-02 | 2006-08-10 | Teva Pharmaceutical Industries, Ltd. | Process for producing polypeptide mixtures using hydrogenolysis |
PL1848415T3 (pl) * | 2005-02-17 | 2013-10-31 | Teva Pharma | Terapia kombinowana obejmująca octan glatirameru oraz rasagilinę do leczenia stwardnienia rozsianego |
WO2006116602A2 (en) * | 2005-04-25 | 2006-11-02 | Yeda Research And Development Company | Markers associated with the therapeutic efficacy of glatiramer acetate |
US8105611B2 (en) * | 2005-06-17 | 2012-01-31 | Allergan, Inc. | Treatment of autoimmune disorder with a neurotoxin |
US8137677B2 (en) * | 2005-10-06 | 2012-03-20 | Allergan, Inc. | Non-protein stabilized clostridial toxin pharmaceutical compositions |
US8168206B1 (en) | 2005-10-06 | 2012-05-01 | Allergan, Inc. | Animal protein-free pharmaceutical compositions |
US20090038701A1 (en) | 2006-01-17 | 2009-02-12 | Baxter International Inc. | Device, system and method for mixing |
EP2213245B1 (en) * | 2006-01-17 | 2012-07-04 | Baxter International Inc. | Device and method for mixing |
CN101479607B (zh) | 2006-04-28 | 2013-10-02 | 莫门塔制药股份有限公司 | 评估肽混合物的方法 |
ITMI20061274A1 (it) * | 2006-06-30 | 2008-01-01 | Consiglio Nazionale Ricerche | Vettori nanoparticellari lipidici contenenti riluzolo e composizioni farmaceutiche che li contengono |
CA2705046C (en) | 2007-07-31 | 2015-03-03 | Natco Pharma Limited | Process for the preparation glatiramer acetate (copolymer-1) |
CA2695634C (en) | 2007-08-06 | 2018-01-23 | Serenity Pharmaceuticals Corporation | Methods and devices for desmopressin drug delivery |
EP2044951A1 (en) | 2007-10-02 | 2009-04-08 | Merz Pharma GmbH & Co. KGaA | The use of substances for the treatment of loss of eyesight in humans with glaucoma and other degenerative eye diseases |
US20090149541A1 (en) * | 2007-11-28 | 2009-06-11 | Yafit Stark | Method of delaying the onset of clinically definite multiple sclerosis |
CN101945654B (zh) * | 2007-12-14 | 2012-06-27 | 江崎格力高株式会社 | α-硫辛酸纳米颗粒及其制备方法 |
WO2009129018A1 (en) | 2008-04-16 | 2009-10-22 | Momenta Pharmaceuticals, Inc. | Analysis of amino acid copolymer compositions |
US11963995B2 (en) | 2008-05-21 | 2024-04-23 | Ferring B.V. | Methods comprising desmopressin |
DK3225250T3 (da) * | 2008-05-21 | 2019-11-04 | Ferring Bv | Orodispersibel desmopressin til forlængelse af den indledende søvnperiode, som ikke forstyrres af nykturi |
US20100286045A1 (en) | 2008-05-21 | 2010-11-11 | Bjarke Mirner Klein | Methods comprising desmopressin |
ES2537022T3 (es) * | 2008-08-07 | 2015-06-01 | Sigma-Aldrich Co. Llc | Preparación de polilisina y poliornitina de bajo peso molecular con alto rendimiento |
BRPI0918718A2 (pt) * | 2008-08-07 | 2015-12-01 | Scinopharm Taiwan Ltd | síntese de acetato de glatirâmero |
AR074881A1 (es) * | 2008-12-24 | 2011-02-16 | Synthon Bv | Un proceso para purificar una mezcla de polimeros |
SG10201505101VA (en) | 2009-05-19 | 2015-07-30 | Neuroderm Ltd | Compositions For Continuous Administration Of Dopa Decarboxylase Inhibitors |
WO2010135731A1 (en) * | 2009-05-22 | 2010-11-25 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
US8299079B2 (en) | 2009-05-22 | 2012-10-30 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
CA2697570C (en) * | 2009-07-15 | 2011-11-01 | Teva Pharmaceutical Industries, Ltd. | Reduced volume formulation of glatiramer acetate and methods of administration |
US8920373B2 (en) | 2009-07-15 | 2014-12-30 | Teva Pharmaceutical Industries, Ltd. | Reduced volume formulation of glatiramer acetate and methods of administration |
WO2011011594A2 (en) * | 2009-07-23 | 2011-01-27 | Shriners Hospitals For Children | Intracellular toll-like receptors pathways and axonal degeneration |
ME02414B (me) * | 2009-07-30 | 2016-09-20 | Teva Pharma | Tretman kronove bolesti lakvinimodom |
EP3064206B1 (en) * | 2009-08-10 | 2019-03-20 | Active Biotech AB | Treatment of huntington's disease using laquinimod |
KR20170123354A (ko) | 2009-08-20 | 2017-11-07 | 에다 리서치 앤드 디벨럽먼트 컴퍼니 리미티드 | 글라티라머 아세테이트를 포함하는 약제 |
EP2509596B1 (en) | 2009-12-08 | 2019-08-28 | Case Western Reserve University | Gamma aminoacids for treating ocular disorders |
USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
US8641661B2 (en) | 2010-01-05 | 2014-02-04 | Baxter International Inc. | Mixing system, kit and mixer adapter |
CA2726566A1 (en) * | 2010-01-11 | 2011-07-11 | Baxter International Inc. | Pipette system, pipette tip assembly and kit |
BR112012021905A2 (pt) * | 2010-03-03 | 2015-09-29 | Teva Pharma | tratamento de nefrite lúpica usando laquinimod |
JP5819328B2 (ja) * | 2010-03-03 | 2015-11-24 | テバ ファーマシューティカル インダストリーズ リミティド | ラキニモドとメトトレキセートとの組合せによる関節リウマチの治療 |
US8759302B2 (en) | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
US9109006B2 (en) * | 2010-07-29 | 2015-08-18 | Santhanakrishnan Srinivasan | Glatiramer acetate molecular weight markers |
SG187770A1 (en) | 2010-08-12 | 2013-03-28 | Univ Nanyang Tech | A liposomal formulation for ocular drug delivery |
JP2013541010A (ja) | 2010-10-11 | 2013-11-07 | テバ ファーマシューティカル インダストリーズ リミティド | グラチラマーアセテートに対する臨床的な反応の予測可能なバイオマーカーとしてのサイトカインバイオマーカー |
HUE037005T2 (hu) | 2010-11-15 | 2018-08-28 | Neuroderm Ltd | L-dopának, dopa dekarboxiláz inhibitoroknak, katechol-O-metil transzferáz inhibitoroknak és ezekhez szolgáló kompozícióknak folyamatos bevezetése |
US20120123094A1 (en) * | 2010-11-17 | 2012-05-17 | Sigma-Aldrich Co. Llc. | Greener method for the production of copolymer 1 |
WO2012078591A1 (en) * | 2010-12-07 | 2012-06-14 | Teva Pharmaceutical Industries Ltd. | Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients |
ES2716865T3 (es) * | 2011-02-18 | 2019-06-17 | Scripps Research Inst | Diferenciación dirigida de células precursoras de oligodendrocitos a un destino celular mielinizante |
AU2012230880B2 (en) | 2011-03-24 | 2017-04-13 | Opko Pharmaceuticals, Llc | Biomarker discovery in complex biological fluid using bead or particle based libraries and diagnostic kits and therapeutics |
US9040082B2 (en) | 2011-06-24 | 2015-05-26 | K-Pax Pharmaceuticals, Inc. | Compositions and methods for treatment of chronic fatigue |
WO2013009864A1 (en) | 2011-07-11 | 2013-01-17 | Momenta Pharmaceuticals, Inc. | Structure assessment of heterogeneous polypeptide mixtures |
WO2013009885A2 (en) | 2011-07-11 | 2013-01-17 | Momenta Pharmaceuticals, Inc. | Evaluation of copolymer diethylamide |
US8575198B1 (en) | 2011-09-07 | 2013-11-05 | Momenta Pharmaceuticals, Inc. | In-process control for the manufacture of glatiramer acetate |
TW201326399A (zh) | 2011-10-10 | 2013-07-01 | Teva Pharma | 用於預測對格拉替雷(glatiramer)醋酸鹽之臨床反應之單核苷酸多型性之判定 |
US8889627B2 (en) | 2011-10-12 | 2014-11-18 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
AU2012330728A1 (en) * | 2011-11-03 | 2014-06-26 | Biocon Limited | Process for the preparation of random polypeptides and employing circular dichroism as a guidance tool for the manufacture of glatiramer acetate |
AU2012354125A1 (en) * | 2011-12-12 | 2014-07-24 | Biocon Limited | Development of specific immunoassay critical reagents for Pharmacokinetic assessments of peptide polymers in preclinical and clinical matrices |
CN104093310A (zh) | 2012-02-03 | 2014-10-08 | 泰华制药工业有限公司 | 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途 |
TW201347762A (zh) * | 2012-05-02 | 2013-12-01 | Teva Pharma | 高劑量拉喹莫德(laquinimod)於治療多發性硬化症之用途 |
ES2715028T3 (es) | 2012-06-05 | 2019-05-31 | Neuroderm Ltd | Composiciones que comprenden apomorfina y ácidos orgánicos y sus usos |
TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療gaba媒介之疾病之拉喹莫德(laquinimod) |
TW201420111A (zh) | 2012-10-10 | 2014-06-01 | Teva Pharma | 對格拉默醋酸鹽(glatiramer acetate)之臨床反應具預測性之生物標記 |
US20150246061A1 (en) * | 2012-10-19 | 2015-09-03 | Celus Pharmaceuticals, Inc. | Vitamin d analogues for the treatment of a neurological disorder |
US9931417B2 (en) | 2012-12-13 | 2018-04-03 | Immunomedics, Inc. | Antibody-SN-38 immunoconjugates with a CL2A linker |
US9107960B2 (en) | 2012-12-13 | 2015-08-18 | Immunimedics, Inc. | Antibody-SN-38 immunoconjugates with a CL2A linker |
JP6553018B2 (ja) | 2013-03-14 | 2019-07-31 | マイラン・インコーポレイテッドMylan Inc. | 酢酸グラチラマー応答バイオマーカーmRNA効力アッセイ |
UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
US9995734B2 (en) | 2013-10-24 | 2018-06-12 | Mylan Inc. | Human T cell line assay for evaluating the immunologic identity of glatiramer acetate preparations |
US9956195B2 (en) | 2014-01-07 | 2018-05-01 | Nanyang Technological University | Stable liposomal formulations for ocular drug delivery |
US10022320B2 (en) | 2014-03-13 | 2018-07-17 | Neuroderm, Ltd. | Dopa decarboxylase inhibitor compositions |
US10258585B2 (en) | 2014-03-13 | 2019-04-16 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
WO2015195605A1 (en) * | 2014-06-17 | 2015-12-23 | Teva Pharmaceutical Industries Ltd. | Transmucosal delivery of glatiramer acetate by oral patches |
CN105218646B (zh) * | 2014-06-24 | 2018-09-21 | 深圳翰宇药业股份有限公司 | 一种用于检测醋酸格拉替雷样本的uplc方法 |
CN104844697B (zh) * | 2014-09-26 | 2018-10-23 | 深圳翰宇药业股份有限公司 | 醋酸格拉替雷的制备方法 |
US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
US20180164275A1 (en) * | 2015-04-30 | 2018-06-14 | Teva Pharmaceutical Industries Ltd. | Method of determining the molecular weight distribution of glatiramer acetate using multi-angle laser light scattering (malls) |
AU2017257254B2 (en) | 2016-04-27 | 2022-02-24 | Immunomedics, Inc. | Efficacy of anti-Trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors |
CN107550853B (zh) * | 2016-06-30 | 2020-06-12 | 深圳翰宇药业股份有限公司 | 一种醋酸格拉替雷注射液的制备方法 |
RU2019110875A (ru) | 2016-09-13 | 2020-10-15 | Аллерган, Инк. | Небелковые композиции клостридиального токсина |
CN110382052A (zh) | 2017-03-26 | 2019-10-25 | Mapi医药公司 | 用于治疗进展型形式的多发性硬化症的格拉替雷储库*** |
US10918734B2 (en) | 2017-03-27 | 2021-02-16 | Immunomedics, Inc. | Treatment of high Trop-2 expressing triple negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51 |
US10799597B2 (en) | 2017-04-03 | 2020-10-13 | Immunomedics, Inc. | Subcutaneous administration of antibody-drug conjugates for cancer therapy |
US20190202984A1 (en) * | 2018-01-03 | 2019-07-04 | Kinbio Ltd. | Process of preparing glatiramer acetate |
US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
US11213502B1 (en) | 2020-11-17 | 2022-01-04 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
US11497765B1 (en) | 2022-02-27 | 2022-11-15 | King Abdulaziz University | Thioctamer expedites wound healing |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3846550A (en) * | 1971-01-21 | 1974-11-05 | H Akrongold | Cosmetic skin powder containing urea |
IL36670A (en) * | 1971-04-21 | 1974-09-10 | Sela M | Therapeutic basic copolymers of amino acids |
JPS6053535A (ja) | 1983-09-02 | 1985-03-27 | Nitto Boseki Co Ltd | 規則性ポリアミノ酸樹脂の製造方法 |
SU1182051A1 (ru) | 1984-04-28 | 1985-09-30 | Таджикский государственный университет им.В.И.Ленина | Политрипептиды,обладающие энантовой селективностью в реакци х гидролиза @ -нитрофениловых эфиров карбобензокси - @ - и @ -аланина |
EP0378246B1 (en) | 1985-06-18 | 1992-03-11 | Emory University | Biologically active copolymers |
DD257174A3 (de) | 1985-12-20 | 1988-06-08 | Ve Forschungszentrum Biotechno | Verfahren zur herstellung der peptide z-ala-ala-lon-p-nitranilid oder z-asp-phe-ome mit metalloprotease |
SU1469826A1 (ru) | 1986-05-30 | 1995-11-20 | Институт Высокомолекулярных Соединений Ан Ссср | Сополимер l-лизина с l-глутаминовой кислотой, содержащий дофаминовые боковые группы, обладающий пролонгированной гипотензивной активностью и компенсаторным эффектом при геморрагическом шоке, и способ его получения |
CA2009996A1 (en) * | 1989-02-17 | 1990-08-17 | Kathleen S. Cook | Process for making genes encoding random polymers of amino acids |
SU1690368A1 (ru) | 1989-07-20 | 1995-08-20 | Институт Высокомолекулярных Соединений Ан Ссср | Статистические сополимеры в качестве низкотоксичных веществ, обладающих пролонгированным гипотензивным действием, и способ их получения |
DE3930733A1 (de) | 1989-09-14 | 1991-03-28 | Roehm Gmbh | Verfahren zur herstellung eines komplexierten arzneimittels |
US5668117A (en) * | 1991-02-22 | 1997-09-16 | Shapiro; Howard K. | Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments |
US5800808A (en) * | 1994-05-24 | 1998-09-01 | Veda Research And Development Co., Ltd. | Copolymer-1 improvements in compositions of copolymers |
US5639726A (en) * | 1994-09-30 | 1997-06-17 | The Regents Of The University Of Michigan | Peptide mediated enhancement of thrombolysis methods and compositions |
US5858964A (en) * | 1995-04-14 | 1999-01-12 | Yeda Research And Development Co. Ltd. | Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD |
IL119989A0 (en) | 1997-01-10 | 1997-04-15 | Yeda Res & Dev | Pharmaceutical compositions for oral treatment of multiple sclerosis |
US6214791B1 (en) * | 1997-01-10 | 2001-04-10 | Yeda Research And Development Co. Ltd. | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 |
WO2000005250A1 (en) | 1998-07-23 | 2000-02-03 | Yeda Research And Development Co., Ltd | Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides |
ES2527760T3 (es) * | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
EP1105414A2 (en) * | 1998-07-23 | 2001-06-13 | President And Fellows of Harvard College | Synthetic peptides and methods of use for autoimmune disease therapies |
US6800287B2 (en) * | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
US6514938B1 (en) * | 1998-09-25 | 2003-02-04 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
ES2327301T3 (es) | 1998-09-25 | 2009-10-27 | Yeda Research And Development Co., Ltd. | Polipeptidos relacionados con el copolimero 1 para su uso como marcadores de pesos moleculares y para uso terapeutico. |
EP1128839A4 (en) | 1998-11-12 | 2002-10-09 | Yeda Res & Dev | PHARMACEUTICAL COMPOSITIONS CONTAINING COPOLYMERS OF SYNTHETIC PEPTIDES AND METHODS FOR PREVENTING AND TREATING GVHD AND HVGD |
CN100360180C (zh) * | 2000-01-20 | 2008-01-09 | 耶达研究及发展有限公司 | 共聚物1和相关肽和多肽及其处理过的t细胞在神经保护性治疗中的用途 |
ZA200206457B (en) * | 2000-02-18 | 2003-08-13 | Yeda Res & Dev | Oral, nasal and pulmonary dosage formulations of copolymer 1. |
DE60120648D1 (de) | 2000-02-18 | 2006-07-27 | Yeda Res & Dev | Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung |
EP1292279A4 (en) | 2000-06-05 | 2005-01-12 | Teva Pharma | USE OF GLATIRAMER ACETATE (COPOLYMER 1) FOR TREATING DISEASES OF THE CENTRAL NERVOUS SYSTEM |
US20020077278A1 (en) * | 2000-06-05 | 2002-06-20 | Yong V. Wee | Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
WO2002076503A1 (en) * | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
US7429374B2 (en) * | 2001-12-04 | 2008-09-30 | Teva Pharmaceutical Industries, Ltd. | Process for the measurement of the potency of glatiramer acetate |
US7309334B2 (en) * | 2002-07-23 | 2007-12-18 | Von Hoffmann Gerard | Intracranial aspiration catheter |
EP1565486A2 (en) | 2002-11-13 | 2005-08-24 | Apotex Pharmachem Inc. | Process for the preparation of glatiramer acetate by polymerisation of n-carboxy anhydrides of l-alanine, l-tyrosine, benzyl l-glutamate and benzyloxycarbonyl l-lysine |
US8008258B2 (en) * | 2003-01-21 | 2011-08-30 | Yeda Research And Development Co. Ltd. | Cop 1 for treatment of inflammatory bowel diseases |
EP1603530A1 (en) * | 2003-03-04 | 2005-12-14 | Teva Pharmaceutical Industries Limited | Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis |
SI1638589T1 (sl) * | 2003-05-14 | 2014-07-31 | Teva Pharmaceutical Industries Ltd. | Kombinirana terapija z glatiramer acetatom in mitoksantronom za zdravljenje multiple skleroze |
NZ546379A (en) * | 2003-10-31 | 2010-04-30 | Teva Pharma | Nanoparticles for drug delivery |
WO2005048435A1 (de) * | 2003-11-13 | 2005-05-26 | Sew-Eurodrive Gmbh & Co. Kg | Kompaktantrieb |
JP2007535498A (ja) * | 2004-03-03 | 2007-12-06 | テバ ファーマシューティカル インダストリーズ リミティド | グラチラマー・アセテートおよびリルゾールでの併用療法 |
NZ554018A (en) * | 2004-09-09 | 2009-06-26 | Teva Pharma | Process for preparation of trifluoroacetyl glatiramer acetate using purified hydrobromic acid |
SI1797109T1 (sl) * | 2004-09-09 | 2016-07-29 | Yeda Research And Development Co., Ltd. | Zmesi polipeptidov, sestavki, ki jih vsebujejo, in postopki za njihovo pripravo ter njihove uporabe |
CA2583589C (en) | 2004-10-29 | 2012-04-24 | Sandoz Ag | Processes for preparing glatiramer |
WO2006083608A1 (en) * | 2005-02-02 | 2006-08-10 | Teva Pharmaceutical Industries, Ltd. | Process for producing polypeptide mixtures using hydrogenolysis |
WO2007030573A2 (en) * | 2005-09-09 | 2007-03-15 | Yeda Research And Development Co. Ltd. | Polypeptides useful for molecular weight determinations |
US20070161566A1 (en) * | 2006-01-11 | 2007-07-12 | Teva Pharmaceutical Industries, Ltd. | Method of treating multiple sclerosis |
SI2046817T1 (sl) | 2006-07-05 | 2010-04-30 | Momenta Pharmaceuticals Inc | Izboljšani postopek za pripravo kopolimera-1 |
-
2005
- 2005-09-09 SI SI200532068A patent/SI1797109T1/sl unknown
- 2005-09-09 PL PL05795337.4T patent/PL1797109T3/pl unknown
- 2005-09-09 EP EP05795337.4A patent/EP1797109B1/en active Active
- 2005-09-09 DK DK05795337.4T patent/DK1797109T3/en active
- 2005-09-09 ES ES05795337.4T patent/ES2572811T3/es active Active
- 2005-09-09 US US11/223,408 patent/US7560100B2/en active Active
- 2005-09-09 HU HUE05795337A patent/HUE028833T2/en unknown
- 2005-09-09 WO PCT/US2005/032553 patent/WO2006029411A2/en active Application Filing
-
2006
- 2006-09-29 US US11/541,263 patent/US20070054857A1/en not_active Abandoned
-
2007
- 2007-03-08 IL IL181802A patent/IL181802A/en active IP Right Grant
-
2016
- 2016-04-28 HR HRP20160455TT patent/HRP20160455T1/hr unknown
- 2016-05-24 CY CY20161100457T patent/CY1117704T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP1797109B1 (en) | 2016-02-24 |
ES2572811T3 (es) | 2016-06-02 |
CY1117704T1 (el) | 2017-05-17 |
EP1797109A4 (en) | 2009-06-17 |
IL181802A0 (en) | 2007-07-04 |
HRP20160455T1 (hr) | 2016-07-15 |
US7560100B2 (en) | 2009-07-14 |
US20070054857A1 (en) | 2007-03-08 |
HUE028833T2 (en) | 2017-01-30 |
WO2006029411A2 (en) | 2006-03-16 |
EP1797109A2 (en) | 2007-06-20 |
US20060122113A1 (en) | 2006-06-08 |
DK1797109T3 (en) | 2016-04-11 |
SI1797109T1 (sl) | 2016-07-29 |
WO2006029411A3 (en) | 2006-08-03 |
IL181802A (en) | 2016-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20160455T1 (hr) | Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene | |
IL195580A (en) | L – fkbp polypeptides, preparations containing them, methods of preparation and use | |
IL169500A0 (en) | Pyrrolopyridazine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same | |
IL181618A0 (en) | Pharmaceutical solid-in-oil compositions for external administraton, methods for preparation and uses thereof | |
IL209386A0 (en) | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | |
IL182947A0 (en) | Chimeric polypeptides and pharmaceutical compositions containing the same | |
IL180397A0 (en) | Diamine derivatives, fungicidal compositions containing the same, and processes for the preparation thereof | |
IL183346A0 (en) | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | |
ZA200800781B (en) | Powdered lime composition, method of preparing same and use thereof | |
PL1765967T3 (pl) | Mieszany proszek lub mieszany granulat na bazie mgda | |
ZA200701689B (en) | Silane compositions, processes for their preparation and rubber compositions containing same | |
ZA200702226B (en) | Compounds, compositions containing them, preparations thereof and uses thereof II | |
PL1751249T3 (pl) | Kompozycje samorzutnie wydzielające parę wodną, wyroby obejmujące takie kompozycje i sposoby wytwarzania takich kompozycji | |
IL177143A0 (en) | Compositions, methods and uses for a novel family of peptides | |
IL183928A0 (en) | Bcma polypeptides, their preparation and pharmaceutical compositions containing them | |
IL182126A (en) | Preparations containing and used in the history of 5-phenoxyalkoxypsoralen | |
IL183044A0 (en) | 2-alcoxy-3,4,5-trihydroxy-alkylamides, preparation thereof, compositions containing them and use thereof | |
IL154370A0 (en) | Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same | |
ZA200801896B (en) | Slow-release composition, method for the preparation thereof, and use of the same | |
EP1797078A4 (en) | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THESE DERIVATIVES, PREPARATION AND USES THEREOF | |
IL179530A0 (en) | Novel compounds, pharmaceutical compositions containing same and methods of use for same | |
IL181683A0 (en) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
ZA200700397B (en) | Novel benzamidine derivatives, process for the preparation thereof and pharmaceutical composition comprising the same | |
ZA200704925B (en) | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | |
EP1797077A4 (en) | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND APPLICATIONS THEREOF |